Compare TTSH & ACIU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | TTSH | ACIU |
|---|---|---|
| Founded | 1985 | 2003 |
| Country | United States | Switzerland |
| Employees | N/A | N/A |
| Industry | Blank Checks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 279.3M | 213.3M |
| IPO Year | N/A | 2016 |
| Metric | TTSH | ACIU |
|---|---|---|
| Price | $4.10 | $3.02 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $10.00 |
| AVG Volume (30 Days) | 696.6K | ★ 1.4M |
| Earning Date | 11-04-2025 | 11-04-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $338,787,000.00 | $5,482,957.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $738.95 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $3.60 | $1.43 |
| 52 Week High | $7.75 | $4.00 |
| Indicator | TTSH | ACIU |
|---|---|---|
| Relative Strength Index (RSI) | 15.05 | 50.19 |
| Support Level | $6.41 | $2.87 |
| Resistance Level | $7.45 | $3.45 |
| Average True Range (ATR) | 0.38 | 0.31 |
| MACD | -0.27 | 0.03 |
| Stochastic Oscillator | 13.10 | 38.09 |
Tile Shop Holdings Inc is a specialty retailer of natural stone and man-made tiles, setting and maintenance materials, and related accessories in the United States. It manufactures its setting and maintenance materials, such as thinset, grout, and sealers. The company's primary market is retail sales to consumers, contractors, designers and home builders. Natural stone products include marble, travertine, granite, quartz, sandstone, slate, and onyx tiles. Man-made products include ceramic, porcelain, glass, cement, wood look, metal and luxury vinyl tile.
AC Immune SA is a clinical-stage biopharmaceutical company that focuses on neurodegenerative diseases. The company uses its proprietary technology platforms to discover, design, and develop novel proprietary small molecules, antibodies, and vaccines for the prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding. The Company has one segment. The Company currently focuses mostly of its resources on discovering and developing therapeutic and diagnostic products targeting misfolded proteins. The company's pipeline consists of ACI-24.060, Crenezumab, ACI-35.030, Semorinemab, ACI-7104.056, and others.